GTBL Acquisition Builds Japan CDMO Platform, Adds Rs 557 Crore Revenue
Key highlights
- MBJ reported FY26 revenue of Rs 557 crore and EBITDA of Rs 138 crore, with a 25% EBITDA margin.
- GTBL’s acquisition adds three GMP-compliant Japanese plants to its existing 990-kilolitre Valsad facility.
- Proprietary pharmaceuticals accounted for 34.2% of MBJ’s FY26 revenue, ahead of contract pharmaceuticals at 29.2%.
- GTBL disclosed Rs 1,351 crore of purchase consideration and Rs 632 crore of separate MBJ loan refinancing.
powered by IRIS

Gujarat Themis Biosyn Limited is using its acquisition of MicroBioPharm Japan to build a Japan-based contract development and manufacturing organisation (CDMO) platform, with MicroBioPharm Japan reporting FY26 revenue of Rs 557 crore, operating three Good Manufacturing Practice (GMP)-compliant plants and adding plasmid DNA, antibody-drug conjugate and bioconversion capabilities beyond GTBL’s rifamycin active pharmaceutical ingredient base.
Know Gujarat Themis Biosyn inside out
Results, valuation, peers and who's buying, in one view.
How does the MBJ acquisition change GTBL?
The acquisition changes GTBL’s stated strategic direction from a fermentation-based active pharmaceutical ingredient (API) and intermediate manufacturer into a fermentation-based CDMO serving pharmaceutical, non-pharmaceutical and biologics customers. Before the transaction, GTBL had one manufacturing facility at Valsad, Gujarat, with 990 kilolitres of capacity and a portfolio focused on rifa-based intermediates, anti-tuberculosis products and anti-infectives.
MicroBioPharm Japan, referred to as MBJ, adds three plants in Japan and access to Asia, Japan and Europe, according to the presentation. GTBL identifies Japan as a market with difficult entry and says it intends to combine its fermentation experience with MBJ’s technology and customer base to pursue new products, projects and markets.
The added portfolio includes fermentation-based immunosuppressants, oncology APIs and anti-infectives. GTBL says the combined business is moving up the value chain from anti-tuberculosis and anti-infective APIs toward specialty small molecules, biologics and gene therapy, supported by capabilities in peptides, plasmids, antibody-drug conjugates (ADCs), bioconversion and precision fermentation.
What revenue mix does MBJ bring to GTBL?
MBJ brings six revenue streams, led by proprietary pharmaceuticals at 34.2% and contract pharmaceuticals at 29.2% of FY26 revenue. Contract pharmaceuticals for biologics represented 16.6%, non-pharmaceuticals 15.2%, developed pharmaceuticals for biologics 3.4%, and developed pharmaceuticals 1.4%.
The segment descriptions show that MBJ’s work spans both commercial and development-stage activity. Its contract pharmaceuticals business includes commercial osteoporosis and arterial-occlusion therapies as well as development projects, while biologics contract work includes recombinant proteins and commercialised products such as Carperitide, Imunace and Immunomax.
Proprietary pharmaceuticals cover sales of anthracycline anticancer drugs and antibiotics in Japan and overseas. Developed pharmaceuticals include investigational-drug manufacturing and analytical fees before product launch, while developed pharmaceuticals for biologics include clinical-stage products such as plasmid-based gene-therapy items. This is broader than GTBL’s existing rifa-based intermediate portfolio.
MBJ generated 59% of FY26 revenue in Japan, 24% in Asia and 17% in Europe. Its top eight customers accounted for more than about 70% of revenue, with disclosed contract periods ranging from six years for Customers E and F in Japan to 40 years for Customer H in Japan; Customers A and D, both overseas accounts, each had 36-year contract periods.
Which CDMO technologies does GTBL gain?
GTBL gains an end-to-end CDMO platform that the presentation says can support drug discovery, clinical development and commercial manufacturing. The manufacturing stage uses GMP systems and multi-product, multi-scale operations covering fermentation, microbial transformation and chemical synthesis, while development work focuses on production efficiency, process simplification and productivity.
Plasmid DNA manufacturing is one acquired biological capability. MBJ is described as a GMP-compliant plasmid DNA manufacturer supplying Japanese and international pharmaceutical companies, with support extending from early research to commercial supply. This capability is part of GTBL’s stated move toward biologics and gene-therapy-related work.
The platform also includes ez-ADiCon, MBJ’s proprietary enzyme-based ADC conjugation technology. The process joins an antibody and drug payload in two steps: deglycosylation and conjugation. MBJ also has a proprietary P450 enzyme library that the presentation says can reduce complex 20-step syntheses to two steps and provide optimised samples in about four months.
Got a follow-up? Ask IRIS
What are MBJ’s financial record and acquisition funding?
MBJ’s FY26 revenue was Rs 557 crore, up from Rs 520 crore in FY25 but below Rs 568 crore in FY24. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose to Rs 138 crore in FY26 from Rs 92 crore in FY25 and Rs 113 crore in FY24, while EBITDA margin increased to 25% from 18% in FY25 and 20% in FY24.
The presentation states that the financial figures are prepared under Japanese generally accepted accounting principles. From FY25 to FY26, revenue increased by Rs 37 crore, EBITDA increased by Rs 46 crore and EBITDA margin rose by seven percentage points.
GTBL lists total purchase consideration of Rs 1,351 crore for MBJ, including payments for stock options and bonus pay. The stated funding sources were Rs 727 crore from a qualified institutional placement, Rs 493 crore from India non-convertible debentures (NCDs) described as mezzanine financing, and Rs 131 crore from Singapore NCD mezzanine financing.
What growth plan does management disclose for MBJ?
Management’s disclosed small-molecule plan is to expand overseas sales of pipeline products for which MBJ holds manufacturing and distribution rights. It also lists market-share gains through price cuts enabled by process optimisation, margin improvement through a wider contract scope for the existing pipeline, and clinical-stage pipeline products with a high-demand outlook.
For biologics, management lists entry into the European and US plasmid market, CDMO opportunities for immunosuppressants and precision fermentation, and use of the P450 enzyme platform for bioconversion. These are stated growth priorities rather than financial forecasts, and the presentation provides no revenue or margin target for these initiatives.
The transaction funding also includes a separate Rs 632 crore refinancing of MBJ’s existing loan. That refinancing uses Rs 443 crore of Singapore NCD mezzanine financing and Rs 189 crore of MBJ cash utilisation, separating debt repayment from the Rs 1,351 crore purchase consideration.
Conclusion
GTBL’s acquisition changes the group’s operating profile by combining its 990-kilolitre Valsad fermentation base with MBJ’s three Japanese GMP-compliant plants, Rs 557 crore of FY26 revenue and a portfolio spanning proprietary products, contract manufacturing and biologics. The platform adds plasmid DNA, ADC conjugation and P450-enabled bioconversion to GTBL’s established anti-infective and rifa-based intermediate activities.
The next areas to watch are management’s stated plan to enter European and US plasmid markets, expand contract opportunities in immunosuppressants and precision fermentation, and pursue small-molecule process optimisation. MBJ’s FY26 EBITDA margin of 25%, following 18% in FY25, provides a reported baseline for future execution, while the Rs 632 crore refinancing remains part of the disclosed transaction structure.


